Abstract:521 Objectives: Glucose transport is a vital component of the metabolic process. The rate of glucose transport from plasma to tissue cells can be quantified using dynamic 18F-FDG PET via the estimation of the K1 parameter in compartmental modeling. However, the accuracy of K1 quantification may be compromised by the assumption of standard compartmental modeling that radiotracer is instantaneously mixed in the blood compartment and ignores that a capillary flow period may exist before the radiotracer is actually transported into tissue cells. In this study, we use high-temporal resolution (HTR) dynamic imaging with a newly developed time-varying kinetic model to better quantify glucose transport. Methods: Two FDG-PET studies were conducted. Prior IRB approval and informed consent were obtained in all cases. The first study involved 14 patient scans with the kidneys in the field of view of a standard PET scanner (GE Discovery 690). Dynamic PET data were reconstructed into HTR 2-s time frames for the first 2 minutes post injection. Regional time activity curves (TACs) were extracted from dynamic images in the renal cortex. The TAC from the descending aorta was used as the image-derived input function (IDIF) for kinetic modeling. The second study was performed using the EXPLORER, a 2-meter long high-sensitivity PET scanner, capable of total-body dynamic imaging. A healthy human subject was scanned and the data of the first 3 minutes were reconstructed into 110 HTR time frames (60x1s, 30x2s, 20x3s). Regional TACs were extracted from regions of interest (ROI) including renal cortex, white matter, gray matter, and myocardium. The left ventricle TAC was used as the IDIF. In both studies, regional TACs were fitted using the standard one-tissue compartmental model with time-invariant kinetics and a new time-varying model which explicitly incorporates the blood flow component in addition to the glucose transport rate K1. These two models were compared for TAC fitting using the Akaike information criterion (AIC). Results: In the first study, the new time-varying model fit the renal TACs more closely than the standard time-invariant model, particularly for the peak values. The corresponding impulse response functions of the two fits indicated the difference and connection between conventional K1 by the standard model and flow-corrected K1 by the new model. Conventional K1 values were 1.09±0.18 ml/g/min in renal cortex. In comparison, the flow-corrected K1 estimates were 0.55±0.15 ml/g/min. The reduction is due to the fact that the new model takes into account the effect of renal blood flow (estimated values: 1.54±0.40 ml/g/min) in the kinetic parameter estimation. The result also indicates conventional FDG K1 estimation is likely a mix of glucose transport rate and blood flow. The time-varying model achieved lower AIC values in all patients, indicating better fit quality by the new model. In the second study using EXPLORER, the time-varying model also better fitted the TACs than the standard model according to both visual fit quality and statistical AIC evaluation. Compared with the flow-corrected K1 estimates, conventional K1 estimates were 40%-60% higher in the renal cortex and myocardium and about 5% higher in gray matter and white matter. The AIC difference further confirmed the new model provided a better fit for different organ ROIs. Conclusion: Glucose transport rate K1 may be overestimated by conventional compartmental modeling due to the effect of partial blood flow involved in the kinetic parameter estimation. With HTR dynamic imaging, this overestimation of K1 can be corrected using a time-varying model. While there was no ground truth available for validation in our studies, the statistical fit evaluation using AIC suggests the new model is more appropriate for quantification of glucose transport. Our future work will further validate the method by correlating flow-corrected K1 with the expression of glucose transporters in cancer and fatty liver disease.

Developing a Method to Estimate the Downstream Metabolite Signals from Hyperpolarized [1-13C]Pyruvate

Abstract 535: Mathematical Modeling of Hyperpolarized Pyruvate Metabolism in Human Heart

Kinetic Modelling and Inference of Hyperpolarized 13C Molecules in Cancer Metabolism

Monitoring Early Glycolytic Flux Alterations Following Radiotherapy in Cancer and Immune Cells: Hyperpolarized Carbon-13 Magnetic Resonance Imaging Study

In vivo Metabolic Sensing of Hyperpolarized [1‐13 C]Pyruvate in Mice Using a Recyclable Perfluorinated Iridium Signal Amplification by Reversible Exchange Catalyst

Real‐Time Metabolic Magnetic Resonance Spectroscopy of Pancreatic and Colon Cancer Tumor‐Xenografts with Parahydrogen Hyperpolarized 1‐13C Pyruvate‐d3

Hyperpolarized product selective saturating-excitations for determination of changes in metabolic reaction rates in real-time

A pharmacokinetic model for hyperpolarized 13C‐pyruvate MRI when using metabolite‐specific bSSFP sequences

In Vivo Molecular Imaging of Breast Cancer Metabolic Heterogeneity Using [1-13C]Pyruvate-d3 Hyperpolarized By Reversible Exchange With Parahydrogen

Current Methods for Hyperpolarized [1-13C]pyruvate MRI Human Studies

Mutual-Information Based Optimal Experimental Design for Hyperpolarized $^{13}$C-Pyruvate MRI

Characterizing Metabolic Heterogeneity of Hepatocellular Carcinoma with Hyperpolarized 13C Pyruvate MRI and Mass Spectrometry

Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study

Yeast Solutions and Hyperpolarization Enable Real-Time Observation of Metabolized Substrates Even at Natural Abundance

Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients

Current methods for hyperpolarized [1‐13C]pyruvate MRI human studies

Rapid Probing of Glucose Influx into Cancer Cell Metabolism: Using Adjuvant and a pH-Dependent Collection of Central Metabolites to Improve In-Cell D-DNP NMR

Specialized Computational Methods for Denoising, B1 Correction, and Kinetic Modeling in Hyperpolarized 13 C MR EPSI Studies of Liver Tumors.

Hyperpolarized 13 C MRI : State of the Art and Future Directions

Quantification of Glucose Transport Using High Temporal Resolution Dynamic PET Imaging

Direct Arterial Injection of Hyperpolarized 13c‐labeled Substrates into Rat Tumors for Rapid MR Detection of Metabolism with Minimal Substrate Dilution